• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Schrödinger Reports Strong First Quarter 2025 Financial Results

    5/7/25 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SDGR alert in real time by email

    First Quarter Total Revenue of $59.6 Million, Software Revenue of $48.8 Million

    Initial SGR-1505 Phase 1 Clinical Data to be Presented in June

    Maintains 2025 Financial Guidance

    Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended March 31, 2025.

    "We are very pleased with Schrödinger's performance in the first quarter of 2025, with strong software and drug discovery revenue growth. Our proprietary pipeline is progressing, and we are looking forward to reporting initial data from the Phase 1 clinical study of SGR-1505 next month," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "More broadly, the pharmaceutical industry and even regulatory agencies are seeking to increase usage of computational solutions in R&D, and we continue to fortify our position as a scientific powerhouse in this field. With our growing software business and advancing pipeline of collaborative and proprietary programs, we believe we have a solid foundation that positions us for long-term growth."

    First Quarter 2025 Financial Results

    • Total revenue for the first quarter increased 63% to $59.6 million, compared to $36.6 million in the first quarter of 2024.
    • Software revenue for the first quarter increased 46% to $48.8 million, compared to $33.4 million in the first quarter of 2024. The increase was primarily due to early renewals by large customers as well as increases in hosted contracts and contribution revenue.
    • Drug discovery revenue was $10.7 million for the first quarter, compared to $3.2 million in the first quarter of 2024. First quarter 2025 drug discovery revenue included the recognition of $5.7 million from the company's collaboration with Novartis.
    • Software gross margin was 72% for the first quarter, compared to 76% in the first quarter of 2024, primarily reflecting the costs associated with the company's predictive toxicology initiative.
    • Operating expenses were $82.0 million for the first quarter, compared to $86.3 million for the first quarter of 2024. The decrease was primarily due to lower R&D expenses.
    • Other expense was $8.9 million for the first quarter, which included changes in fair value of equity investments and interest income/expense, compared to other income of $13.2 million for the first quarter of 2024.
    • Net loss for the first quarter was $59.8 million, compared to $54.7 million in the first quarter of 2024.

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

     

    % Change

     

    (in millions)

     

     

    Total revenue

    $

    59.6

     

     

    $

    36.6

     

     

    63

    %

    Software revenue

     

    48.8

     

     

     

    33.4

     

     

    46

    %

    Drug discovery revenue

     

    10.7

     

     

     

    3.2

     

     

    237

    %

    Software gross margin

     

    72

    %

     

     

    76

    %

     

     

    Operating expenses

    $

    82.0

     

     

    $

    86.3

     

     

    (5.0

    )%

    Other (expense) income

    $

    (8.9

    )

     

    $

    13.2

     

     

    —

     

    Net loss

    $

    (59.8

    )

     

    $

    (54.7

    )

     

    —

     

    For the three months ended March 31, 2025, Schrödinger reported a net loss of $59.8 million, compared to a net loss of $54.7 million for the three months ended March 31, 2024.

    For the three months ended March 31, 2025, Schrödinger reported a non-GAAP net loss of $46.7 million, compared to a non-GAAP net loss of $62.4 million for the three months ended March 31, 2024. See "Non-GAAP Information" below and the table at the end of this press release for a reconciliation of non-GAAP net loss to GAAP net loss.

    2025 Financial Outlook

    As of May 7, 2025, Schrödinger maintained its previously issued financial guidance for the fiscal year ending December 31, 2025:

    • Software revenue growth is expected to range from 10% to 15%.
    • Drug discovery revenue is expected to range from $45 million to $50 million.
    • Software gross margin is expected to range from 74% to 75%.
    • Operating expense growth in 2025 is expected to be less than 5%.
    • Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024.

    For the second quarter of 2025, software revenue is expected to range from $38 million to $42 million.

    Key Highlights

    Proprietary and Collaborative Pipeline

    • Schrödinger continues to progress the Phase 1 clinical study of SGR-1505, the company's MALT1 inhibitor, in patients with relapsed/refractory B-cell malignancies and expects to report initial clinical data from the trial in June.
    • Schrödinger is continuing to progress the Phase 1 clinical study of SGR-2921, its CDC7 inhibitor, in patients with AML and myelodysplastic syndrome (MDS). The company expects to report initial data from this trial at a medical meeting in the second half of 2025.
    • Schrödinger is continuing to progress the Phase 1 clinical study of SGR-3515, the company's Wee1/Myt1 co-inhibitor, in patients with advanced solid tumors. Initial clinical data from this study are expected in the second half of 2025. In April, Schrödinger presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting demonstrating that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors.
    • Also at the AACR Annual Meeting, Schrödinger presented initial preclinical data for SGR-4174, the company's investigational SOS1 inhibitor. The preclinical data demonstrated that SGR-4174 exhibited potent and selective SOS1 inhibition and has strong tumor growth inhibition as a monotherapy and in combination with MEK or KRAS inhibitors.

    Platform

    • In April, the company issued a statement following the FDA's announcement outlining plans to reduce existing animal testing requirements for monoclonal antibodies and other drugs with new approaches, including computation. Schrödinger is advancing its predictive toxicology initiative focused on small molecules, which is expected to be available to customers in the second half of 2025. The company currently offers computational solutions for small molecules and biologics that can be used to evaluate selectivity and the potential for off-target interactions.
    • In March, Schrödinger scientists published research in Nature Communications describing a novel, computational crystal structure prediction (CSP) method that predicts crystal polymorphs with a high degree of accuracy and reliability. The ability to quickly and accurately predict crystal polymorphs has important applications for drug formulation.

    Corporate

    • In March, Schrödinger appointed Bridget van Kralingen to its Board of Directors. Ms. van Kralingen brings more than 35 years of experience leading and growing global technology solution and software businesses and is currently a senior partner at Motive Partners, an investment firm focused on technology-enabled companies. Prior to Motive Partners, Ms. van Kralingen spent nearly 18 years in a variety of executive roles at IBM, including as chief executive/senior vice president of IBM Global Markets and as chief executive of IBM's Industry Platforms software division.

    Webcast and Conference Call Information

    Schrödinger will host a conference call to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website, https://ir.schrodinger.com/news-and-events/event-calendar. To participate in the live call, please register for the call here. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will receive the dial-in information. The archived webcast will be available on Schrödinger's website for approximately 90 days following the event.

    Non-GAAP Information

    Included in this press release is certain financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The company presents non-GAAP net income (loss) and non-GAAP net income (loss) per share, which exclude gains and losses on equity investments, changes in fair value of equity investments, and income tax benefits and expenses. Adjusting net income to exclude the impact of these items results in a financial presentation for the company without the impact of our equity investments and tax benefits and expenses. Management believes non-GAAP net income (loss) and non-GAAP net income (loss) per share are useful measures for investors, taken in conjunction with the company's GAAP financial statements because they provide greater period-over-period comparability with respect to the company's operating performance, by excluding non-cash mark-to-market and other valuation adjustments for the company's equity investments, non-recurring cash distributions from the company's equity investments and the tax impact of these distributions that are not reflective of the ongoing operating performance of the business. However, the non-GAAP measures should be considered only in addition to, not as a substitute for or as superior to, net income (loss) and net income (loss) per share or other financial measures prepared in accordance with GAAP.

    Other companies in Schrödinger's industry may calculate non-GAAP net income (loss) and non-GAAP net income (loss) per share, differently than we do, limiting their usefulness as comparative measures. For a reconciliation of non-GAAP net income (loss) and non-GAAP net income (loss) per share to GAAP net income (loss) and GAAP net income (loss) per share, respectively, please refer to the tables at the end of this press release.

    About Schrödinger

    Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 900 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding Schrödinger's expectations about the speed and capacity of its computational platform, its financial outlook for the fiscal year ending December 31, 2025 and second quarter ending June 30, 2025, its plans to continue to invest in research and its strategic plans to accelerate the growth of its software business and advance its collaborative and proprietary drug discovery programs, the long-term potential of its business, its ability to improve and advance the science underlying its platform, including the ability to predict off-target activity, its ability to improve drug discovery and the timing during which the predictive toxicology initiative's technology will become available to software customers and collaborators, the initiation, timing, progress, and results of its proprietary drug discovery programs and product candidates and the drug discovery programs and product candidates of its collaborators, the clinical potential and favorable properties of its MALT1, CDC7, Wee1/Myt1, and SOS1 inhibitors, including SGR-1505, SGR-2921, SGR-3515, and SGR-4174, the clinical potential and favorable properties of its collaborators' product candidates, as well as expectations related to the use of its cash, cash equivalents and marketable securities. Statements including words such as "aim," "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goal," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger's current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger's control, including the demand for its software platform, its ability to further develop its computational platform, its reliance upon third-party providers of cloud-based infrastructure to host its software solutions, factors adversely affecting the life sciences industry, fluctuations in the value of the U.S. dollar and foreign currencies, its reliance upon its third-party drug discovery collaborators, the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of IND submissions, clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and other risks detailed under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 7, 2025, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.

    Condensed Consolidated Statements of Operations (Unaudited)

    (in thousands, except for share and per share amounts)

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

    Revenues:

     

     

     

    Software products and services

    $

    48,816

     

     

    $

    33,415

     

    Drug discovery

     

    10,735

     

     

     

    3,183

     

    Total revenues

     

    59,551

     

     

     

    36,598

     

    Cost of revenues:

     

     

     

    Software products and services

     

    13,522

     

     

     

    7,976

     

    Drug discovery

     

    14,905

     

     

     

    9,732

     

    Total cost of revenues

     

    28,427

     

     

     

    17,708

     

    Gross profit

     

    31,124

     

     

     

    18,890

     

    Operating expenses:

     

     

     

    Research and development

     

    45,844

     

     

     

    50,611

     

    Sales and marketing

     

    10,367

     

     

     

    10,171

     

    General and administrative

     

    25,802

     

     

     

    25,541

     

    Total operating expenses

     

    82,013

     

     

     

    86,323

     

    Loss from operations

     

    (50,889

    )

     

     

    (67,433

    )

    Other (expense) income:

     

     

     

    Gain on equity investments

     

    —

     

     

     

    —

     

    Change in fair value of equity investments

     

    (13,095

    )

     

     

    8,137

     

    Other income

     

    4,204

     

     

     

    5,028

     

    Total other (expense) income

     

    (8,891

    )

     

     

    13,165

     

    Loss before income taxes

     

    (59,780

    )

     

     

    (54,268

    )

    Income tax expense

     

    28

     

     

     

    456

     

    Net loss

    $

    (59,808

    )

     

    $

    (54,724

    )

    Net loss per share of common and limited common stockholders, basic and diluted:

    $

    (0.82

    )

     

    $

    (0.76

    )

    Weighted average shares used to compute net loss per share of common and limited common stockholders, basic and diluted:

     

    73,057,916

     

     

     

    72,291,134

     

    Condensed Consolidated Balance Sheets (Unaudited)

    (in thousands, except for share and per share amounts)

     

    Assets

    March 31,

    2025

     

    December 31,

    2024

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    325,997

     

     

    $

    147,326

     

    Restricted cash

     

    11,764

     

     

     

    15,331

     

    Marketable securities

     

    174,301

     

     

     

    204,798

     

    Accounts receivable, net of allowance for doubtful accounts of $210 and $210

     

    20,347

     

     

     

    235,692

     

    Unbilled and other receivables, net of allowance for unbilled receivables of $120 and $100

     

    25,973

     

     

     

    19,641

     

    Prepaid expenses

     

    12,562

     

     

     

    12,205

     

    Total current assets

     

    570,944

     

     

     

    634,993

     

    Property and equipment, net

     

    22,937

     

     

     

    24,196

     

    Equity investments

     

    30,113

     

     

     

    43,208

     

    Goodwill

     

    4,791

     

     

     

    4,791

     

    Right of use assets - operating leases

     

    109,661

     

     

     

    111,883

     

    Other assets

     

    4,586

     

     

     

    4,155

     

    Total assets

    $

    743,032

     

     

    $

    823,226

     

    Liabilities and Stockholders' Equity:

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

     

    11,861

     

     

    $

    10,666

     

    Accrued payroll, taxes, and benefits

     

    21,494

     

     

     

    42,110

     

    Deferred revenue

     

    105,458

     

     

     

    111,944

     

    Lease liabilities - operating leases

     

    16,755

     

     

     

    16,755

     

    Other accrued liabilities

     

    9,904

     

     

     

    10,272

     

    Total current liabilities

     

    165,472

     

     

     

    191,747

     

    Deferred revenue, long-term

     

    104,496

     

     

     

    108,814

     

    Lease liabilities - operating leases, long-term

     

    99,405

     

     

     

    101,074

     

    Other liabilities, long-term

     

    155

     

     

     

    146

     

    Total liabilities

     

    369,528

     

     

     

    401,781

     

    Stockholders' equity:

     

     

     

    Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively

     

    —

     

     

     

    —

     

    Common stock, $0.01 par value. Authorized 500,000,000 shares; 64,179,002 and 63,710,409 shares issued and outstanding at March 31, 2025 and December 31, 2024 , respectively

     

    642

     

     

     

    637

     

    Limited common stock, $0.01 par value. Authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively

     

    92

     

     

     

    92

     

    Additional paid-in capital

     

    958,029

     

     

     

    946,037

     

    Accumulated deficit

     

    (585,349

    )

     

     

    (525,541

    )

    Accumulated other comprehensive income

     

    90

     

     

     

    220

     

    Total stockholders' equity

     

    373,504

     

     

     

    421,445

     

    Total liabilities and stockholders' equity

    $

    743,032

     

     

    $

    823,226

     

    Condensed Consolidated Statements of Cash Flows (Unaudited)

    (in thousands)

     

     

    Three Months Ended March 31,

     

     

    2025

     

     

     

    2024

     

    Cash flows from operating activities:

     

     

     

    Net loss

    $

    (59,808

    )

     

    $

    (54,724

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Gain on equity investments

     

    —

     

     

     

    —

     

    Fair value adjustments of equity investments

     

    13,095

     

     

     

    (8,137

    )

    Depreciation and amortization

     

    1,589

     

     

     

    1,436

     

    Stock-based compensation

     

    11,574

     

     

     

    12,218

     

    Noncash investment accretion

     

    (861

    )

     

     

    (2,683

    )

    Decrease (increase) in assets:

     

     

     

    Accounts receivable, net

     

    215,345

     

     

     

    46,153

     

    Unbilled and other receivables

     

    (6,332

    )

     

     

    (2,657

    )

    Reduction in the carrying amount of right of use assets - operating leases

     

    2,222

     

     

     

    2,152

     

    Prepaid expenses and other assets

     

    (788

    )

     

     

    (2,559

    )

    Increase (decrease) in liabilities:

     

     

     

    Accounts payable

     

    1,344

     

     

     

    (7,150

    )

    Accrued payroll, taxes, and benefits

     

    (20,616

    )

     

     

    (12,214

    )

    Deferred revenue

     

    (10,804

    )

     

     

    (7,761

    )

    Lease liabilities - operating leases

     

    (1,669

    )

     

     

    (1,967

    )

    Other accrued liabilities

     

    (228

    )

     

     

    (1,383

    )

    Net cash provided by (used in) operating activities

     

    144,063

     

     

     

    (39,276

    )

    Cash flows from investing activities:

     

     

     

    Purchases of property and equipment

     

    (596

    )

     

     

    (4,095

    )

    Purchases of marketable securities

     

    (27,556

    )

     

     

    (37,126

    )

    Proceeds from maturity of marketable securities

     

    58,784

     

     

     

    46,300

     

    Net cash provided by investing activities

     

    30,632

     

     

     

    5,079

     

    Cash flows from financing activities:

     

     

     

    Issuances of common stock upon stock option exercises

     

    423

     

     

     

    392

     

    Principal payments on finance leases

     

    (14

    )

     

     

    (14

    )

    Payment of offering costs

     

    —

     

     

     

    (155

    )

    Issuance of common stock in ATM offering

     

    —

     

     

     

    7,782

     

    Net cash provided by financing activities

     

    409

     

     

     

    8,005

     

    Net increase (decrease) in cash and cash equivalents and restricted cash

     

    175,104

     

     

     

    (26,192

    )

    Cash and cash equivalents and restricted cash, beginning of period

     

    162,657

     

     

     

    161,066

     

    Cash and cash equivalents and restricted cash, end of period

    $

    337,761

     

     

    $

    134,874

     

     

     

     

     

    Supplemental disclosure of cash flow and noncash information

     

     

     

    Cash paid for income taxes

    $

    139

     

     

    $

    180

     

    Supplemental disclosure of non-cash investing and financing activities

     

     

     

    Purchases of property and equipment in accounts payable

     

    13

     

     

     

    501

     

    Purchases of property and equipment in accrued liabilities

     

    25

     

     

     

    282

     

    Acquisition of right of use assets - operating leases, contingency resolution

     

    —

     

     

     

    2,848

     

    Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

     

    (in thousands, except per share data)

    Net loss (GAAP)

    $

    (59,808

    )

     

    $

    (54,724

    )

    Income tax expense

     

    28

     

     

     

    456

     

    Gain on equity investment

     

    —

     

     

     

    —

     

    Change in fair value

     

    13,095

     

     

     

    (8,137

    )

    Non-GAAP net loss

    $

    (46,685

    )

     

    $

    (62,405

    )

    Non-GAAP net loss per share of common and limited common stockholders, basic and diluted:

    $

    (0.64

    )

     

    $

    (0.86

    )

    Weighted average shares used to compute non-GAAP net loss per share of common and limited common stockholders, basic and diluted:

     

    73,057,916

     

     

     

    72,291,134

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507908616/en/

    Matthew Luchini (Investors)

    Schrödinger, Inc.

    [email protected]

    917-719-0636

    Allie Nicodemo (Media)

    Schrödinger, Inc.

    [email protected]

    617-356-2325

    Get the next $SDGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SDGR

    DatePrice TargetRatingAnalyst
    7/2/2024$29.00Outperform
    Leerink Partners
    12/5/2023$38.00Overweight
    KeyBanc Capital Markets
    5/5/2023$60.00Overweight
    Piper Sandler
    12/19/2022$23.00Neutral
    Goldman
    3/1/2022$55.00Buy
    Citigroup
    11/19/2021$82.00 → $49.00Overweight → Equal-Weight
    Morgan Stanley
    11/19/2021$87.00Overweight
    Piper Sandler
    11/11/2021$80.00 → $52.00Buy → Neutral
    B of A Securities
    More analyst ratings

    $SDGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Schrodinger with a new price target

      Leerink Partners initiated coverage of Schrodinger with a rating of Outperform and set a new price target of $29.00

      7/2/24 8:03:41 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KeyBanc Capital Markets initiated coverage on Schrodinger with a new price target

      KeyBanc Capital Markets initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $38.00

      12/5/23 8:08:54 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Schrodinger with a new price target

      Piper Sandler resumed coverage of Schrodinger with a rating of Overweight and set a new price target of $60.00

      5/5/23 8:17:18 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    SEC Filings

    See more
    • SEC Form S-8 filed by Schrodinger Inc.

      S-8 - Schrodinger, Inc. (0001490978) (Filer)

      5/7/25 4:25:07 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Schrodinger Inc.

      10-Q - Schrodinger, Inc. (0001490978) (Filer)

      5/7/25 4:09:21 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrodinger Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Schrodinger, Inc. (0001490978) (Filer)

      5/7/25 4:07:32 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Schrodinger Inc.

      SC 13G - Schrodinger, Inc. (0001490978) (Subject)

      11/13/24 4:30:25 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

      SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

      2/13/24 5:13:59 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

      SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

      1/23/24 11:52:31 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Leadership Updates

    Live Leadership Updates

    See more

    $SDGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SDGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

      Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch

      3/10/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

      Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim

      8/18/22 7:01:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Announces Appointment of Arun Oberoi to Board of Directors

      Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi will serve as a member of the Audit Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005040/en/Arun Oberoi was appointed to Schrödinger's Board of Directors in May 2022. He will serve on the company's Audit Committee. (Photo: Business Wire) "We are very pleased to welcome Arun to our Board," said Ramy Farid, Ph.D., president and chief executive officer of Schrödinger. "Aru

      5/19/22 7:00:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President of R&D, Therapeutics Akinsanya Karen exercised 16,723 shares at a strike of $3.16 and sold $419,570 worth of shares (16,723 units at $25.09) (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      4/15/25 4:31:21 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Van Kralingen Bridget A was granted 10,000 shares (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      3/10/25 4:35:57 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Van Kralingen Bridget A

      3 - Schrodinger, Inc. (0001490978) (Issuer)

      3/10/25 4:31:29 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Reports Strong First Quarter 2025 Financial Results

      First Quarter Total Revenue of $59.6 Million, Software Revenue of $48.8 Million Initial SGR-1505 Phase 1 Clinical Data to be Presented in June Maintains 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended March 31, 2025. "We are very pleased with Schrödinger's performance in the first quarter of 2025, with strong software and drug discovery revenue growth. Our proprietary pipeline is progressing, and we are looking forward to reporting initial data from the Phase 1 clinical study of SGR-1505 next month," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "More broadly, the pharmaceutical industry and even regulator

      5/7/25 4:05:00 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AI Healthcare Boom Gains Speed as Regulators and Innovators Align

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 5, 2025 /PRNewswire/ --The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating. According to research from PYMNTS Intelligence which polled C-suite executives at healthcare companies generating at least $1 billion in annual revenue, 90% already see positive ROI from investments in generative AI (GenAI). Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of a baseline $2.26 trillion. Behind the scenes, several new AI healthcare tech developments are taking place, with updates rec

      5/5/25 12:35:00 PM ET
      $GEHC
      $SDGR
      $TEM
      $TVGN
      Medical Electronics
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Software: Programming Data Processing
    • Schrödinger to Present at BofA Securities 2025 Healthcare Conference

      Schrödinger, Inc. (NASDAQ:SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on Wednesday, May 14, 2025 at 4:40 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biot

      5/5/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Financials

    Live finance-specific insights

    See more
    • Schrödinger Reports Strong First Quarter 2025 Financial Results

      First Quarter Total Revenue of $59.6 Million, Software Revenue of $48.8 Million Initial SGR-1505 Phase 1 Clinical Data to be Presented in June Maintains 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended March 31, 2025. "We are very pleased with Schrödinger's performance in the first quarter of 2025, with strong software and drug discovery revenue growth. Our proprietary pipeline is progressing, and we are looking forward to reporting initial data from the Phase 1 clinical study of SGR-1505 next month," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "More broadly, the pharmaceutical industry and even regulator

      5/7/25 4:05:00 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger to Announce First Quarter 2025 Financial Results on May 7

      Schrödinger (NASDAQ:SDGR) will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutic

      4/23/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

      Achieved 2024 Software Revenue of $180.4 Million, a 13.3% Increase Over 2023 Expects Software Revenue Growth of 10% to 15% and Drug Discovery Revenue of $45-50 Million in 2025 Announces Expanded Research Collaboration with Eli Lilly and Company On Track to Report Initial Phase 1 Data from Three Proprietary Programs in 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2024, and provided its financial outlook for 2025. "We are delighted with Schrödinger's excellent financial performance in 2024. Software revenue growth exceeded our expectations, showing the resilience of our business through changing indust

      2/26/25 4:05:00 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care